YI HU1,#, ZHONGYANG REN2,#, ZHENGZHONG ZHAO1, YONGJIA HUANG3, WANTING HUANG3, JIE LIU3,*, LING DING3,*
BIOCELL, Vol.48, No.5, pp. 745-758, 2024, DOI:10.32604/biocell.2024.049140
- 06 May 2024
Abstract Background: Acute pancreatitis (AP), known for its rapid onset and significant incidence and mortality rates, presents a clinical challenge due to the limited availability of effective treatments and preventive measures. Anemarsaponin B (ASB) has emerged as a potential therapeutic agent, demonstrating capabilities in reducing immune inflammation, positioning it as a promising candidate for AP treatment. Methods: We investigated the effects of ASB on AP in mice, induced by caerulein and lipopolysaccharide (LPS). Peripheral blood samples were collected 24 h post-induction with caerulein to assess of key biomarkers including lipase, amylase, TNF-α, IL-1β, IL-6, SOD, and… More >